Organovo

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

Retrieved on: 
Thursday, January 25, 2024
Probability, Biology, Fibrosis, Organovo, SAN, Tissue, IBD, Inflammatory bowel disease, Cirrhosis, Research and development, Disease, 3D, NASH, Colitis, Ulcerative colitis, FXR, Pharmaceutical industry

FXR314 is a clinical-stage potent, selective, orally administered non-bile acid FXR agonist being developed as a novel therapeutic approach for IBD.

Key Points: 
  • FXR314 is a clinical-stage potent, selective, orally administered non-bile acid FXR agonist being developed as a novel therapeutic approach for IBD.
  • FXR314 broadly improved measures of epithelial barrier function in a subset of donors, and fibrotic markers in all Crohn’s disease donors.
  • In ulcerative colitis, FXR314 improved epithelial barrier function and fibrotic activity in all donors.
  • Organovo plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 2024, with targeted completion in 2025.

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress

Retrieved on: 
Tuesday, January 9, 2024
Biology, Fibrosis, Organovo, UC, SAN, Partnership, Tissue, IBD, Inflammatory bowel disease, Executive, Cirrhosis, Research and development, Disease, 3D, NASH, Colitis, Ulcerative colitis, FXR, Ulcer

The invited oral presentation, entitled “Evaluation of the clinical stage FXR agonist FXR314 in human primary cell 3D models of Crohn’s disease and ulcerative colitis”, will be made on Friday, January 26, 2024 at 3:00 PM PST by Dr. Fabrice Piu, Vice President, Research & Development.

Key Points: 
  • The invited oral presentation, entitled “Evaluation of the clinical stage FXR agonist FXR314 in human primary cell 3D models of Crohn’s disease and ulcerative colitis”, will be made on Friday, January 26, 2024 at 3:00 PM PST by Dr. Fabrice Piu, Vice President, Research & Development.
  • “We initially identified a strong benefit of FXR agonism in IBD using our internal 3D models, then moved towards development of what we believe to be a best-in-class FXR agonist, FXR314, to treat IBD,” said Keith Murphy, Organovo's Executive Chairman.
  • Organovo plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 1H 2024, with targeted completion in 1H 2025.
  • The drug’s additional promise in liver fibrosis and NASH makes it a strong candidate for development in that area through partnership collaborations with Organovo.

Organovo Highlights FXR314 Combination Therapy Potential and Plan

Retrieved on: 
Monday, November 13, 2023
3D, ILC, Organovo, Cytokine, JAK, Ulcerative colitis, Tissue, Disease, Biology, IBD, Bacteria, Safety, Patient, Inflammatory bowel disease, SAN, Pharmaceutical industry, Tofacitinib, Ustekinumab

The promise of combination therapy in this space is great, as all of these therapies have impactful safety signals.

Key Points: 
  • The promise of combination therapy in this space is great, as all of these therapies have impactful safety signals.
  • Further, FXR314 combination therapy could enable the successful achievement of clinical remission in a greater percentage of patients.
  • Organovo has previously announced plans for a Phase 2a study of FXR314 in ulcerative colitis, with a readout expected in 1H 2025.
  • In addition, the company will now begin preclinical studies with combination therapies using FXR314 and currently approved therapies or equivalent that can benefit from lower dosing.

Organovo to Participate in the H.C. Wainwright Global Investment Conference

Retrieved on: 
Friday, September 8, 2023
Tissue, Lotte New York Palace Hotel, Organovo, Disease, Conference, SAN, Pharmaceutical industry, Hotel, Cryptocurrency

SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

Key Points: 
  • SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.
  • Institutional investors interested in arranging a meeting with management can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel.

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Retrieved on: 
Wednesday, August 23, 2023
Tissue, FXR, NASH, 3D, Clinical trial, Disease, Ulcerative colitis, Phase 1, Patient, SAN, IND, FDA, Safety, Pharmaceutical industry, Organovo

FXR314 is a drug with safety and tolerability after daily oral dosing in Phase 1 and Phase 2 trials.

Key Points: 
  • FXR314 is a drug with safety and tolerability after daily oral dosing in Phase 1 and Phase 2 trials.
  • Further, FXR314 has FDA clinical trial authorization for a Phase 2 trial in ulcerative colitis.
  • “Phase 1 safety data for FXR314, the data in our 3D human models of ulcerative colitis, and preclinical models all show very positive promise for FXR314 in the treatment of ulcerative colitis,” said Keith Murphy, Organovo’s Founder and Executive Chairman.
  • In addition, Organovo is anticipating the release of final Phase 2 data on the performance of FXR314 in NASH.

Fork & Good Introduces the Pork Factory of the Future to make Sustainable Meat More Affordable

Retrieved on: 
Tuesday, March 14, 2023
Retail, Climate Change, Manufacturing, Sustainability, Supply Chain Management, Environment, Environmental Health, Agriculture, Natural Resources, Other Manufacturing, Science, Biotechnology, Food, Beverage, Other Science, Health, Livestock, TEDMED, Meat, Starlight, Hydroponics, Viral, Modern Meadow, Fork, Niya, Cell, Collaborative Fund, Multimedia, B cell, Bayer, Water, Ecosystem, Food industry, Organovo, Good

Combined, these factors have weakened the pork supply chain and contributed to price volatility that threatens to put meat out of reach for many consumers in the near future.

Key Points: 
  • Combined, these factors have weakened the pork supply chain and contributed to price volatility that threatens to put meat out of reach for many consumers in the near future.
  • We're excited to see Fork and Good making progress toward this vision,” said Juergen Eckhardt, Head of Leaps by Bayer.
  • Fork and Good’s initial focus on ground pork aims to help solve supply chain instability in the massive $820 billion global pork market.
  • “Achieving high yields at an affordable price point is incredibly complex, and Fork and Good is uniquely equipped for the task,” said Adam D’Augelli, True Ventures.

Global Bioprinting Technologies and Markets Report 2023 - Growing Momentum Within Enhanced Cybersecurity, Internet of Medical Things, Medical Robots, 3D Printed Objects, & Device Connectivity

Retrieved on: 
Monday, January 23, 2023
USD, 3D bioprinting, Intelligence, Cell, BICO Group, Ceramic, Cosmetics, Gel, Growth, Drug discovery, Tissue engineering, Patient, WHO, Regenerative medicine, Printing, Research, Renewable energy, Pharmaceutical industry, 3D printing, Semiconductor, Organovo

DUBLIN, Jan. 23, 2023 /PRNewswire/ -- The "Bioprinting: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 23, 2023 /PRNewswire/ -- The "Bioprinting: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This report incorporates an in-depth analysis of the bioprinting market, including market estimations and trends through 2020.
  • The report presents a market analysis and estimates the compound annual growth rate (CAGR) for bioprinting technologies.
  • The scope of the report extends to only those bioprinting technologies that generate the most global revenue.

Bioprinting Technologies and Global Markets Report 2023 Featuring Leading Players - 3D Bio, Advanced Solutions, Cellink, Organovo, and Stratasys - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 19, 2023
Biotechnology, Surgery, Medical Devices, Health, Stem Cells, Printing, Cell, Gel, WHO, Ceramic, Cellink, Growth, Drug discovery, Tissue engineering, Patient, Intelligence, Research, Cosmetics, USD, 3D bioprinting, Regenerative medicine, Renewable energy, Pharmaceutical industry, 3D printing, Organovo

This report incorporates an in-depth analysis of the bioprinting market, including market estimations and trends through 2020.

Key Points: 
  • This report incorporates an in-depth analysis of the bioprinting market, including market estimations and trends through 2020.
  • Major players, competitive intelligence, innovative technologies, market dynamics, and regional opportunities are discussed in detail.
  • The report presents a market analysis and estimates the compound annual growth rate (CAGR) for bioprinting technologies.
  • The scope of the report extends to only those bioprinting technologies that generate the most global revenue.

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

Retrieved on: 
Tuesday, November 15, 2022
Abdominal pain, Architecture, SAN, Diarrhea, Weight loss, 3D bioprinting, Prevalence, Gene, IND, Tissue, Risk, Patient, IBD, Fatigue, Annual report, 3D, Inflammation, Disease, Drug development, Ulcer, Malnutrition, Therapy, Quality of life, Fibrosis, Human, Crohn's disease, Biology, Drug discovery, Inflammatory bowel disease, Probability, Pharmaceutical industry, Medical imaging, Organovo

The Crohns disease model has since been utilized to understand the biology of disease and identify specific gene targets.

Key Points: 
  • The Crohns disease model has since been utilized to understand the biology of disease and identify specific gene targets.
  • Organovo plans to advance at least one target program to medicinal chemistry by the end of 2022 to build a proprietary new drug for Crohns disease.
  • The Organovo team has successfully identified disease regulated genes from our Crohn's disease model and importantly, identified a subset that are disease-driver genes, said Jeff Miner, Ph.D., Organovos Chief Scientific Officer.
  • Two early steps that are uniquely important in Organovos approach to drug discovery are creation of a disease model followed by target discovery and validation.

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022
Inflammatory bowel disease, 3D, Interest, SAN, NASDAQ, Disease, Organovo, Tissue, Risk, SEC, GLOBE, Architecture, Conference, Biology, Company, Investor, Annual report, Private Securities Litigation Reform Act, Drug development, Pharmaceutical industry, Security (finance)

Organovo plans to advance drugs discovered in its cutting-edge human 3D disease models in inflammatory bowel disease.

Key Points: 
  • Organovo plans to advance drugs discovered in its cutting-edge human 3D disease models in inflammatory bowel disease.
  • In May 2022, the company announced that it had done so, successfully achieving a 3D tissue model for Crohns Disease.
  • Organovo expects to begin medicinal chemistry on a lead program for Crohns Disease in the first half of 2023.
  • Mr. Murphy will deliver the Organovo corporate presentation and meet with investment community members during the hybrid conference.